<SEC-DOCUMENT>0001185185-23-001027.txt : 20231004
<SEC-HEADER>0001185185-23-001027.hdr.sgml : 20231004
<ACCEPTANCE-DATETIME>20231003192729
ACCESSION NUMBER:		0001185185-23-001027
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20231004
DATE AS OF CHANGE:		20231003
EFFECTIVENESS DATE:		20231004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IGC Pharma, Inc.
		CENTRAL INDEX KEY:			0001326205
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				202760393
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-274853
		FILM NUMBER:		231306129

	BUSINESS ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854
		BUSINESS PHONE:		301-983-0998

	MAIL ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	India Globalization Capital, Inc.
		DATE OF NAME CHANGE:	20050505
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>igcpharma20230929_s8.htm
<DESCRIPTION>FORM S-8
<TEXT>
<html><head>
	<title>igcpharma20230929_s8.htm</title>
	<!-- Generated by ThunderDome Portal - 10/3/2023 11:25:21 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">As filed with the Securities and Exchange Commission on October 3, 2023</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Registration No.&nbsp; <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM S-8</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REGISTRATION STATEMENT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">UNDER</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">THE SECURITIES ACT OF 1933</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="igcpharma20230929_s8img001.jpg" src="igcpharma20230929_s8img001.jpg" style="width:117;height:69;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>IGC PHARMA, INC.</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Maryland</u></b></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>20-2760393</u></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">incorporation or organization)</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification Number)</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>10224 Falls Road</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Potomac, Maryland 20854</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>(301) 983-0998</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address, including zip code, and telephone number,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">including area code, of registrant&#8217;s principal executive offices)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>IGC 2018 Omnibus Incentive Plan</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Special Grants #6</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Special Grants #7</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Full title of the plan)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Claudia Grimaldi</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>IGC Pharma, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>10224 Falls Road</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Potomac, Maryland 20854</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>(301) 983-0998</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name, address, including zip code, and telephone number,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">including area code, of agent for service)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Copy to:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Spencer G. Feldman, Esq.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Olshan Frome Wolosky LLP</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>1325 Avenue of the Americas</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>New York, New York 10019</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>(212) 451-2300</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">&nbsp;</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:17.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer</p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer box.</p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:middle;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:17.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-accelerated filer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Do not check if a smaller reporting company)</p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="vertical-align:middle;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;&#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">&nbsp;</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXPLANATORY NOTE</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Registration Statement on Form S-8 (this &#8220;<b>Registration Statement</b>&#8221;) is being filed by IGC Pharma, Inc., a Maryland corporation (the &#8220;<b>Company</b>&#8221; or the &#8220;<b>Registrant</b>&#8221;), relating to (i) 4,000,000 shares of common stock, par value $0.0001 per share (the &#8220;<b>Common Stock</b>&#8221;), issuable upon the vesting of restricted stock granted to certain employees pursuant to the 2018 Omnibus Incentive Plan of the Registrant (the &#8220;<b>2018 Omnibus Incentive Plan</b>&#8221;) and (ii) 6,000,000 shares of Common Stock, issuable upon the vesting of restricted stocks granted to certain employees pursuant to Special Grant #6 and #7, outside of the Company&#8217;s 2018 Omnibus Incentive Plan.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Registration Statement also includes a prospectus (the &#8220;<b>Reoffer Prospectus</b>&#8221;) prepared in accordance with General Instruction C of Form S-8 and in accordance with the requirements of Part I of Form S-3. This Reoffer Prospectus may be used for the reoffer and resale of shares of Common Stock on a continuous or delayed basis that may be deemed to be &#8220;restricted securities&#8221; and/or &#8220;control securities&#8221; within the meaning of the Securities Act of 1933 as amended (the &#8220;<b>Securities Act</b>&#8221;), and the rules and regulations promulgated thereunder, that are issuable to certain of our executive officers, employees, consultants and directors identified in the Reoffer Prospectus. The number of shares of Common Stock included in the Reoffer Prospectus represents shares of Common Stock issuable to the selling stockholders pursuant to equity awards, including stock options and restricted stock grants, granted to the selling stockholders and does not necessarily represent a present intention to sell any or all such shares of Common Stock. The number of shares of Common Stock to be offered or resold by means of the Reoffer Prospectus by the selling stockholders and any other person with whom any of them is acting in concert for the purpose of selling Common Stock may not exceed, during any three-month period, the amount specified in Rule 144(e) under the Securities Act.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As specified in General Instruction C of Form S-8, until such time as we meet the registrant requirements for the use of Form S-3, the number of shares of Common Stock to be offered by means of this reoffer prospectus, by each of the selling securityholders, and any other person with whom he or she is acting in concert for the purpose of selling our shares of Common Stock, may not exceed, during any three-month period, the amount specified in Rule 144(e) of the Securities Act.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Unless the context requires otherwise, all references in this report to </i>&#8220;<i>IGC,</i>&#8221;<i> </i>&#8220;<i>the Company,</i>&#8221;<i> </i>&#8220;<i>we,</i>&#8221;<i> </i>&#8220;<i>our,</i>&#8221;<i> and/or </i>&#8220;<i>us</i>&#8221;<i> refer to IGC Pharma, Inc., together with our subsidiaries and beneficially owned subsidiary.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">&nbsp;</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>PART I</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:5.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 1.</b></p>
			</td>
			<td style="vertical-align:top;width:41.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Plan Information.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company will provide each recipient of a grant under the Special Grant #6 (the &#8220;<b>Recipients</b>&#8221;) with documents that contain information related to the Special Grant #6, and other information including, but not limited to, the disclosure required by Item 1 of Form S-8, which information is not required to be and is not being filed as a part of this Registration Statement on Form S-8 (the &#8220;<b>Registration Statement</b>&#8221;) or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. The foregoing information and the documents incorporated by reference in response to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives shares of Common Stock covered by this Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 11%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 2.</b></p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Registrant Information and Employee Plan Annual Information.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will provide to each Recipient a written statement advising of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement (which documents are incorporated by reference in this Section 10(a) prospectus) and of documents required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral request by contacting: Claudia Grimaldi at 301-983-0998 or by email at info@igcinc.us.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">&nbsp;</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>REOFFER PROSPECTUS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><img alt="igcpharma20230929_s8img002.jpg" src="igcpharma20230929_s8img002.jpg" style="text-align:center;width:117;height:69;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>10,000,000 Shares</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Common Stock Issuable under the Company</b>&#8217;<b>s 2018 Omnibus Incentive Plan and Under Certain Awards</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Granted Outside of the Company</b>&#8217;<b>s 2018 Omnibus Incentive Plan</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This reoffer prospectus relates to the public resale, from time to time, of an aggregate of 10,000,000 shares (the &#8220;<b>Shares</b>&#8221;) of our common stock, $0.0001 par value per share (the &#8220;<b>Common Stock</b>&#8221;) by certain securityholders identified herein in the section entitled &#8220;Selling Securityholders&#8221;. Such shares may be acquired in connection with the Company&#8217;s Omnibus Incentive Plans and certain awards granted from the Company&#8217;s 2022 and 2023 Special Grant approved by the Company&#8217;s shareholders on September 9, 2022 (the &#8220;<b>Special Grant #6</b>&#8221;) and August 18, 2023 (the &#8220;<b>Special Grant #7</b>&#8221;) (collectively the &#8220;<b>Plans</b>&#8221;). You should read this prospectus carefully before you invest in our Common Stock.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Such resales shall take place on The NYSE American, or such other stock market or exchange on which our Common Stock may be listed or quoted, in negotiated transactions or otherwise, at market prices prevailing at the time of the sale or at prices otherwise negotiated (see &#8220;<b>Plan of Distribution</b>&#8221; starting on page 5 of this prospectus). We will receive no part of the proceeds from sales made under this reoffer prospectus. The Selling Securityholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection with the registration and offering and not borne by the Selling Securityholders will be borne by us.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This reoffer prospectus has been prepared for the purposes of registering our shares of Common Stock under the Securities Act to allow for future sales by Selling Securityholders on a continuous or delayed basis to the public without restriction, provided that the amount of shares of Common Stock to be offered or resold under this Reoffer Prospectus by each Selling Securityholder or other person with whom he or she is acting in concert for the purpose of selling shares of Common Stock, may not exceed, during any three-month period, the amount specified in Rule 144(e) under the Securities Act. We have not entered into any underwriting arrangements in connection with the sale of the shares covered by this reoffer prospectus. The Selling Securityholders identified in this reoffer prospectus, or their pledgees, donees, transferees, or other successors-in-interest, may offer the shares covered by this reoffer prospectus from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Investing in our Common Stock involves risks. See &#8220;Risk Factors&#8221; beginning on page 3 of this reoffer prospectus. These are speculative securities.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our Common Stock is quoted on The NYSE American under the symbol &#8220;IGC&#8221; and the last reported sale price of our Common Stock on September 29, 2023, was $0.36 per share.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this prospectus is October 3, 2023.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">&nbsp;</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="toc" name="toc" title="toc"></a>TABLE OF CONTENTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#cautioon" style="-sec-extract:exhibit;">Cautionary Statement Regarding Forward-Looking Statements</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#prosum" style="-sec-extract:exhibit;">Prospectus Summary</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#rf" style="-sec-extract:exhibit;">Risk Factors</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#use" style="-sec-extract:exhibit;">Use of Proceeds</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#selling" style="-sec-extract:exhibit;">Selling Securityholders</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#plan" style="-sec-extract:exhibit;">Plan of Distribution</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#legal" style="-sec-extract:exhibit;">Legal Matters</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#ex" style="-sec-extract:exhibit;">Experts</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#dis" style="-sec-extract:exhibit;">Disclosure of Commission Position on Indemnification For Securities Act Liabilities</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#where" style="-sec-extract:exhibit;">Where You can Find Additional Information</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#inc" style="-sec-extract:exhibit;">Incorporation of Certain Documents by Reference</a></p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">&nbsp;</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cautioon" name="cautioon" title="cautioon"></a>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This report and the documents incorporated in this report by reference contain &#8220;forward-looking statements.&#8221; We or our representatives may, from time to time, make written or verbal forward-looking statements. In this report and the documents incorporated by reference, we discuss plans, expectations, and objectives regarding our business, financial condition, and results of operations. Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;trend,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;assume,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;target,&#8221; &#8220;anticipate,&#8221; &#8220;outlook,&#8221; &#8220;preliminary,&#8221; &#8220;will likely result,&#8221; &#8220;will continue,&#8221; and variations of them and similar terms are intended to be &#8220;forward-looking statements.&#8221; We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans, and projections. Forward-looking statements are subject to risks and uncertainties, including those identified in the &#8220;Risk Factors&#8221; included in this prospectus and in the documents incorporated by reference that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made. Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations or the occurrence of unanticipated events after the date of those statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Forward-looking statements are based upon, among other things, our assumptions with respect to:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">the sufficiency of our existing cash and cash equivalents and marketable securities to fund our future operating and capital expenses;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our independent registered public accounting firm&#8217;s reports have raised substantial doubt regarding our ability to continue as a &#8220;going concern.&#8221;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to successfully register trademarks and patents, create and market new products and services, including trading in Hong Kong and other parts of South Asia, contract for infrastructure projects and rental of equipment in India, and achieve customer acceptance in the industries we serve;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">current and future economic and political conditions, including in Hong Kong, North America, Colombia, and India;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to accurately predict the future demand for our products and services;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to successfully market our hemp-based products in countries and states where hemp and hemp products are legal;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to maintain a stock listing on a national securities exchange;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to timely complete regulatory filings;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to obtain the U.S. Food and Drug Administration (&#8220;<b>FDA</b>&#8221;) approval for an Investigational New Drug Application (&#8220;<b>INDA</b>&#8221;) and to successfully run medical trials, including a Phase 2 trial for IGC-AD1;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our reliance on third parties to conduct clinical trials, and for the manufacture of IGC-AD1 for non-clinical studies and clinical trials;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">the impact of the COVID-19 pandemic on our results of operations, including the delay in our ability to launch certain projects;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our financial performance;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">the outcome of medical trials that are conducted on our Investigational Drug Candidates and products;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to fund the costs of clinical trials and other related expenses;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to maintain our intellectual property position and our ability to maintain and protect our intellectual property rights;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">competition and general acceptance of phytocannabinoids for alternative, pharmaceutical, and nutraceutical therapies;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to effectively compete and our dependence on market acceptance of our brands and products within and outside the United States;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">federal and state legislation, and administrative policy regulating phytocannabinoids;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability (based in part on regulatory concerns) to license our products to processors that can produce pharmaceutical grade phytocannabinoids;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to obtain and protect patents for the use of phytocannabinoids in our formulations;</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to obtain and install equipment for processing and manufacturing hemp and hemp products; and</p>
			</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="vertical-align: top; width: 2.1%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; width: 44.2%; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">our ability to successfully navigate disruptions of information technology systems or data security breaches that could adversely affect our business.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">You should consider the limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements. As noted above, these forward-looking statements speak only as of the date when they are made. Moreover, in the future, we may make forward-looking statements through our senior management that involve the risk factors and other matters described in this report, as well as other risk factors subsequently identified, including, among others, those identified in our filings with the SEC in our annual report on Form 10-K, quarterly reports on Form 10-Q and our current reports on Form 8-K.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This document contains statements and claims that are not approved by the FDA, including statements on hemp and hemp extracts, including cannabidiol and other cannabinoids. These statements and claims are intended to be in compliance with state laws, specifically in states where medical cannabis has been legalized, and the diseases which we anticipate our products will target are approved conditions for treatment or usage with cannabis or cannabinoids.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="prosum" name="prosum" title="prosum"></a>PROSPECTUS SUMMARY</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The SEC allows us to &#8220;incorporate by reference&#8221; certain information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will update automatically, supplement, and/or supersede the information disclosed in this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other document that also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should read the following summary together with the more detailed information regarding our company, our Common Stock, and our financial statements and notes to those statements appearing elsewhere in this prospectus or incorporated herein by reference.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Our Company</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IGC Pharma, Inc., formerly known as IGC Pharma, Inc., is a clinical-stage pharmaceutical company with a diversified revenue model that develops both prescription drugs and over-the-counter (OTC) products. IGC is a Maryland corporation established in 2005 with a fiscal year that is a 52- or 53-week period that ends on March 31. IGC has two business segments: Life Sciences and Infrastructure.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our focus is on developing innovative therapies for neurological disorders such as Alzheimer&#8217;s disease, epilepsy, Tourette syndrome, and sleep disorders. We also focus on formulations for eating disorders, chronic pain, premenstrual syndrome (PMS), and dysmenorrhea, in addition to health and wellness OTC formulations. The Company is developing its lead candidate, IGC-AD1, an investigational oral therapy for the treatment of agitation associated with Alzheimer&#8217;s disease. IGC-AD1 is currently in Phase 2 (Phase 2B) clinical trials after completing nearly a decade of research and realizing positive results from pre-clinical and a Phase 1 trial. This previous research into IGC-AD1 has demonstrated efficacy in reducing plaques and tangles, which are two important hallmarks of Alzheimer&#8217;s, as well as reducing neuropsychiatric symptoms associated with dementia in Alzheimer&#8217;s disease, such as agitation.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Alzheimer&#8217;s is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. As the most common cause of dementia, it affects over 50 million people worldwide. The disease is associated with the accumulation of plaques and tangles in the brain, leading to brain cell deterioration and impaired cognitive functions. Currently, there is no cure for Alzheimer&#8217;s, and the projected cost of Alzheimer&#8217;s and associated dementia is expected to be around $1 trillion just in the U.S., placing a significant financial strain on individuals, families, and the healthcare system.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The progress we are making in clinical trials gives us confidence in the potential of IGC-AD1 to be a groundbreaking therapy, with the potential to treat Alzheimer&#8217;s and also to manage devastating symptoms that separate families, increase admissions to nursing homes, and drive the cost of Alzheimer&#8217;s care. We have filed forty-one (41) patent applications in different countries and secured nine patents, including control of four in the Alzheimer&#8217;s space. We have built a facility for a potential Phase 3 trial and have strategic relations for the procurement of Active Pharmaceutical Ingredients (APIs). In addition, we have acquired and initiated work on TGR-63, a pre-clinical molecule that exhibits an impressive affinity for reducing neurotoxicity in Alzheimer&#8217;s cell lines. The advancement of IGC-AD1 into Phase 2 trials represents a significant milestone for the Company and positions us for multiple pathways to future success. We anticipate that the positive outcomes from these and other trials will drive further growth, valuation, and market potential for IGC-AD1, although there can be no assurance thereof.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At IGC Pharma, we recognize the significance of operational excellence and cost management in clinical trials. We have established an internal capability to manage trials, including proprietary software, rather than working with an external Contract Research Organization (CRO). We believe this empowers us to substantially reduce the costs associated with clinical trials compared to relying on external CROs. Our proprietary software allows us to streamline the trial processes, enabling seamless coordination and data management. Additionally, we are integrating machine learning technologies into our software framework. We believe this overlay of Artificial Intelligence (AI) will help us simulate trial scenarios, generate new insights to facilitate improved decision-making, efficiently design our Phase 3 trial, provide advanced data analysis, and ultimately enhancing the effectiveness and efficiency of our clinical trials, although there can be no assurance thereof.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Corporate Information</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of October 2, 2023, the Company had the following direct operating subsidiaries: Techni Bharathi Private Limited (&#8220;<b>TBL</b>&#8221;), IGCare, LLC (&#8220;<b>IGCare</b>&#8221;), Holi Hemp, LLC (&#8220;<b>Holi Hemp</b>&#8221;), IGC Pharma, LLC, SAN Holdings, LLC (&#8220;<b>SAN Holdings</b>&#8221;), Sunday Seltzer, LLC (&#8220;<b>Sunday Seltzer</b>&#8221;) and Colombia-based beneficially owned subsidiary IGC Pharma S.A.S. (&#8220;<b>IGC Pharma Col</b>&#8221;) (formerly Hamsa Biochem SAS). The Company&#8217;s fiscal year is the 52-week or 53-week period that ends on March 31. The Company, formerly known as India Globalization Capital, Inc., is a Maryland corporation established in 2005. The Company&#8217;s filings are available on www.sec.gov.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>The Offering</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Outstanding Common Stock:</b></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">63,706,939 shares of our Common Stock are outstanding as of October 2, 2023.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock Offered:</b></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Up to 10,000,000 shares of Common Stock for sale by the selling securityholders (which include our executive officers and directors) for their own account pursuant to the Plans.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Selling Securityholders:</b></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The selling securityholders are set forth in the section entitled &#8220;Selling Securityholders&#8221;&nbsp;of this reoffer prospectus on page 3. The amount of securities to be offered or resold by means of the reoffer prospectus by the designated selling securityholders may not exceed, during any three-month period, the amount specified in Rule 144(e).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of proceeds:</b></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We will not receive any proceeds from the sale of our Common Stock by the selling securityholders. We would, however, receive proceeds upon the exercise of the stock options by those who receive options under the Plans and exercise such options for cash. Any cash proceeds will be used by us for general corporate purposes.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risk Factors:</b></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The securities offered hereby involve a high degree of risk. See &#8220;Risk Factors.&#8221;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NYSE American trading symbol </b></p>
			</td>
			<td style="vertical-align: middle; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 68%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;IGC&#8221;</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="rf" name="rf" title="rf"></a>RISK FACTORS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">An investment in our securities involves a high degree of risk. In addition to the following risk factors, you should carefully consider the risks, uncertainties and assumptions discussed in Item 1A., &#8220;Risk Factors&#8221; of our annual report on Form 10-K for the fiscal year ended March 31, 2023, and in other documents that we subsequently file with the SEC that update, supplement or supersede such information, which documents are incorporated by reference into this reoffer prospectus. Additional risks not presently known to us or which we consider immaterial based on information currently available to us may also materially adversely affect us. If any of the events anticipated by the risks described occur, our results of operations and financial condition could be adversely affected, which could result in a decline in the market price of our common stock, causing you to lose all or part of your investment.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="use" name="use" title="use"></a>USE OF PROCEEDS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The shares which may be sold under this reoffer prospectus will be sold for the respective accounts of each of the Selling Securityholders listed herein (which includes our executive officers and directors). Accordingly, we will not realize any proceeds from the sale of the shares of our Common Stock. We will receive proceeds from the exercise of the options; however, no assurance can be given as to when or if any or all of the options will be exercised. If any options are exercised, the proceeds derived therefrom will be used for working capital and general corporate purposes. All expenses of the registration of the shares will be paid by us. See &#8220;Selling Securityholders&#8221; and &#8220;Plan of Distribution.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="selling" name="selling" title="selling"></a>SELLING SECURITYHOLDERS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are registering for resale the shares covered by this prospectus to permit the Selling Securityholders identified below and their pledgees, donees, transferees, and other successors-in-interest that receive their securities from a Selling Securityholder as a gift, partnership distribution, or other non-sale related transfer after the date of this prospectus to resell the shares when and as they deem appropriate. The Selling Securityholders acquired, or may acquire, these shares from us pursuant to the Plans. The shares may not be sold or otherwise transferred by the Selling Securityholders unless and until the applicable awards vest and are exercised, as applicable, in accordance with the terms and conditions of the Plans.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the name of each Selling Securityholder;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the position(s), office, or other material relationship with our company and its predecessors or affiliates, over the last three years of each Selling Securityholder;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the number and percentage of shares of our Common Stock that each Selling Securityholder beneficially owned as of October 2, 2023, prior to the offering for resale of the shares under this prospectus;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the number of shares of our Common Stock that may be offered for resale for the account of each Selling Securityholder under this prospectus; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the number and percentage of shares of our Common Stock to be beneficially owned by each Selling Securityholder after the offering of the resale shares (assuming all of the offered resale shares are sold by such Selling Securityholder).</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:20pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Information with respect to beneficial ownership is based upon information obtained from the Selling Securityholders. Because the Selling Securityholders may offer all or part of the shares of Common Stock, which they own pursuant to the offering contemplated by this reoffer prospectus, and because its offering is not being underwritten on a firm commitment basis, no estimate can be given as to the amount of shares that will be held upon termination of this offering.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The number of shares in the column &#8220;Number of Shares Being Offered&#8221; represents the shares of our Common Stock that each Selling Securityholder may offer under this prospectus (&#8220;<b>Shares</b>&#8221;). We do not know how long the Selling Securityholders will hold the shares before selling them or how many shares they will sell. The shares of our Common Stock offered by this prospectus may be offered from time to time by the Selling Securityholders listed below. We cannot assure you that any of the Selling Securityholders will offer for sale or sell any or all of the shares of Common Stock offered by them by this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Shares Beneficially</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Owned Prior to Offering (1)</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares Being</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Shares Beneficially</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Owned After Offering (2)</b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Securityholders</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percent (%)</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Offered</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percent (%)</b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".lead.B4">&nbsp;</td>
			<td id=".symb.B4">&nbsp;</td>
			<td id=".amt.B4">&nbsp;</td>
			<td id=".trail.B4">&nbsp;</td>
			<td id=".lead.B5">&nbsp;</td>
			<td id=".symb.B5">&nbsp;</td>
			<td id=".amt.B5">&nbsp;</td>
			<td id=".trail.B5">&nbsp;</td>
			<td id=".lead.B6">&nbsp;</td>
			<td id=".symb.B6">&nbsp;</td>
			<td id=".amt.B6">&nbsp;</td>
			<td id=".trail.B6">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ram Mukunda (3)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,175</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.0</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,441</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,616</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Richard Prins (4)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">913</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.4</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">432</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,345</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.0</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Claudia Grimaldi (5)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">700</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.1</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">484</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,184</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.8</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">James Moran (6)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">133</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.2</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">215</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">348</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.5</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:43.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The number and percentage of shares beneficially owned are determined in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, beneficial ownership includes any shares as to which the Selling Securityholder has sole or shared voting power or investment power and also any shares which the Selling Securityholder has the right to acquire within 60 days. Applicable percentage ownership is based on shares of Common Stock outstanding as of.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:43.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Assumes that all shares of Common Stock to be offered, as set forth above, are sold pursuant to this offering and that no other shares of Common Stock are acquired or disposed of by the Selling Securityholders prior to the termination of this offering. Because the Selling Securityholders may sell all, some, or none of their shares of Common Stock or may acquire or dispose of other shares of Common Stock, no reliable estimate can be made of the aggregate number of shares of Common Stock that will be sold pursuant to this offering or the number or percentage of shares of Common Stock that each Selling Securityholder will own upon completion of this offering.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;width:43.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Mr. Mukunda is our Chief Executive Officer and a member of the Board. The shares of Common Stock beneficially owned prior to this offering represent shares of Common Stock issuable upon settlement of unvested restricted stock grants. The beneficial ownership table does not include shares of common stock that is owned by Mr. Mukunda&#8217;s spouse, for which Mr. Mukunda has no voting or financial rights.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="vertical-align:top;width:43.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Mr. Richard Prins is a member of the Board. The shares of Common Stock registered for resale hereunder represent shares of Common Stock issuable upon settlement of unvested restricted stock grants.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p>
			</td>
			<td style="vertical-align:top;width:43.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Ms. Claudia Grimaldi is our Vice President, PFO, and a member of the Board. The shares of Common Stock registered for resale hereunder represent shares of Common Stock issuable upon settlement of unvested restricted stock grants.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3%;">(6)</td>
			<td style="vertical-align: top; width: 43.3%; text-align: justify;">Mr. James Moran is a member of the Board. The shares of Common Stock registered for resale hereunder represent shares of Common Stock issuable upon settlement of unvested restricted stock grants.</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="plan" name="plan" title="plan"></a>PLAN OF DISTRIBUTION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are registering the Shares covered by this prospectus to permit the Selling Stockholders to conduct public secondary trading of these Shares from time to time after the date of this prospectus. We will not receive any of the proceeds of the sale of the Shares offered by this prospectus. The aggregate proceeds to the Selling Stockholders from the sale of the Shares will be the purchase price of the Shares less any discounts and commissions. We will not pay any brokers&#8217; or underwriters&#8217; discounts and commissions in connection with the registration and sale of the Shares covered by this prospectus. The Selling Stockholders reserve the right to accept and, together with their respective agents, to reject, any proposed purchases of Shares to be made directly or through agents.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Shares offered by this prospectus may be sold from time to time to purchasers:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">directly by the Selling Stockholders, or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">through underwriters, broker-dealers, or agents, who may receive compensation in the form of discounts, commissions, or agent&#8217;s commissions from the Selling Stockholders or the purchasers of the Shares.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any underwriters, broker-dealers, or agents who participate in the sale or distribution of the Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act. As a result, any discounts, commissions, or concessions received by any such broker-dealer or agents who are deemed to be underwriters will be deemed to be underwriting discounts and commissions under the Securities Act. Underwriters are subject to the prospectus delivery requirements of the Securities Act and may be subject to certain statutory liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). We will make copies of this prospectus available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. To our knowledge, there are currently no plans, arrangements, or understandings between the Selling Stockholders and any underwriter, broker-dealer, or agent regarding the sale of the Shares by the Selling Stockholders.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Shares may be sold in one or more transactions at:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fixed prices;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">prevailing market prices at the time of sale;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">prices related to such prevailing market prices;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">varying prices determined at the time of sale; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">negotiated prices.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">These sales may be effected in one or more transactions:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">on any national securities exchange or quotation service on which the Shares may be listed or quoted at the time of sale, including the NYSE;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">in the over-the-counter market;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">in transactions otherwise than on such exchanges or services or in the over-the-counter market;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any other method permitted by applicable law; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">through any combination of the foregoing.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">These transactions may include block transactions or crosses. Crosses are transactions in which the same broker acts as an agent on both sides of the trade.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At the time a particular offering of the Shares is made, a prospectus supplement, if required, will be distributed, which will set forth the name of the Selling Stockholders, the aggregate amount of Shares being offered, and the terms of the offering, including, to the extent required, (1) the name or names of any underwriters, broker-dealers or agents, (2) any discounts, commissions and other terms constituting compensation from the Selling Stockholders and (3) any discounts, commissions or concessions allowed or reallowed to be paid to broker-dealers.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Stockholders will act independently of us in making decisions with respect to the timing, manner, and size of each resale or other transfer. There can be no assurance that the Selling Stockholders will sell any or all of the Shares under this prospectus. Further, we cannot assure you that the Selling Stockholders will not transfer, distribute, devise, or gift the Shares by other means not described in this prospectus. In addition, any Shares covered by this prospectus that qualify for sale under Rule 144 of the Securities Act may be sold under Rule 144 rather than under this prospectus. The Shares may be sold in some states only through registered or licensed brokers or dealers. In addition, in some states, the Shares may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification is available and complied with.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Stockholders and any other person participating in the sale of the Shares will be subject to the Exchange Act. The Exchange Act rules include, without limitation, Regulation M, which may limit the timing of purchases and sales of any of the Shares by the Selling Stockholders and any other person. In addition, Regulation M may restrict the ability of any person engaged in the distribution of the Shares to engage in market-making activities with respect to the particular Shares being distributed. This may affect the marketability of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Stockholders may indemnify any broker or underwriter that participates in transactions involving the sale of the Shares against certain liabilities, including liabilities arising under the Securities Act.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="legal" name="legal" title="legal"></a>LEGAL MATTERS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The validity of the issuance of the securities offered by this prospectus will be passed upon for us by Olshan Frome Wolosky LLP, New York, New York.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="ex" name="ex" title="ex"></a>EXPERTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The consolidated financial statements of IGC Pharma, Inc. included in our annual report on Form 10-K for the fiscal year ended March 31, 2022, and March 31, 2023, have been audited by Manohar Chowdhry &amp; Associates, independent registered public accountants, as set forth in their reports thereon, included therein, and incorporated herein by reference in this prospectus and elsewhere in the registration statement. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on the authority of said firm as experts in accounting and auditing.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="dis" name="dis" title="dis"></a>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FOR SECURITIES ACT LIABILITIES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or persons controlling the registrant, the registrant has been informed that in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="where" name="where" title="where"></a>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We file reports, proxy statements and other documents with the SEC. You may read and copy any document we file at the SEC&#8217;s public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549, subject to restrictions that may be imposed from time to time as a result of the COVID-19 pandemic. You should call 1-800-SEC-0330 for more information on the operation of the public reference room, including any restrictions imposed as a result of the COVID-19 pandemic. Our SEC filings are also available to you on the SEC's Internet site at http://www.sec.gov. The SEC&#8217;s Internet site contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus is part of a registration statement on Form S-8 being filed with the SEC. The registration statement contains more information than this prospectus regarding us and our common stock, including certain exhibits and schedules. You can obtain a copy of the registration statement from the SEC at the address listed above or from the SEC&#8217;s Internet site.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our Internet address is www.igcpharma.com. The information on our Internet website is not incorporated by reference in this prospectus.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>PART II</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="inc" name="inc" title="inc"></a>Item 3. Incorporation of Certain Documents by Reference.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we have filed with it, which means that we can disclose important information to you by referring you to those documents. The documents listed below are hereby incorporated by reference into this Registration Statement:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:43.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Annual Report on Form 10-K for the fiscal year ended March&nbsp;31, 2023, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1326205/000118518523000693/igcpharma20230331_10k.htm" style="-sec-extract:exhibit;">July 7, 2023</a>;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:43.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1326205/000118518523000796/igcpharma20230630_10q.htm" style="-sec-extract:exhibit;">August 10, 2023</a>.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:43.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Current Reports on Form 8-K, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1326205/000118518523000448/igcpharma20230505_8k.htm" style="-sec-extract:exhibit;">May 8, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1326205/000118518523000688/igcpharma20230706_8k.htm" style="-sec-extract:exhibit;">July 7, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1326205/000118518523000691/igcpharma20230706c_8k.htm" style="-sec-extract:exhibit;">July 7, 2023</a> and <a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523000887/igcpharma20230821_8k.htm" style="-sec-extract:exhibit;">August 21, 2023</a>;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:43.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Definitive Proxy Statement on Form DEF 14A as filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523000759/igcpharma20230726_def14a.htm" style="-sec-extract:exhibit;">July 26, 2023</a>.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:43.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The description of our common stock contained in our Registration Statement on Form 8-A filed pursuant to Section 12 of the&nbsp;Exchange Act on <a href="http://www.sec.gov/Archives/edgar/data/1326205/000095013706002699/c03201e8va12b.htm" style="-sec-extract:exhibit;">March 7, 2006</a>, and any amendments or reports filed for the purpose of updating the description.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;<b>Exchange Act</b>&#8221;), after the date hereof and prior to the termination of this offering shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such reports and other documents. Unless expressly incorporated into this Registration Statement, a report furnished but not filed on Form 8-K shall not be incorporated by reference into this Registration Statement. Any document, or any statement contained in a document, incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a document or statement contained herein, or in any other subsequently filed document that also is deemed to be incorporated by reference herein, modifies or supersedes such document or statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Subject to the foregoing, all information appearing in this Registration Statement is qualified in its entirety by the information appearing in the documents incorporated by reference.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 4. Description of Securities.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Not applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 5. Interests of Named Experts and Counsel.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Not applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 6. Indemnification of Directors and Officers.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our certificate of incorporation provides that all directors, officers, employees and agents of the registrant shall be entitled to be indemnified by us to the fullest extent permitted by Section 2-418 of the Maryland General Corporation Law. Section 2-418 of the Maryland General Corporation Law concerning indemnification of officers, directors, employees and agents is set forth below.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#8220;Section 2-418. Indemnification of directors, officers, employees and agents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(a) <i>Definitions</i>. &#8212; In this section the following words have the meanings indicated.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Director&#8221;&nbsp;means any person who is or was a director of a corporation and any person who, while a director of a corporation, is or was serving at the request of the corporation as a director, officer, partner, trustee, employee, or agent of another foreign or domestic corporation, partnership, joint venture, trust, other enterprise, or employee benefit plan.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Corporation&#8221;&nbsp;includes any domestic or foreign predecessor entity of a corporation in a merger, consolidation, or other transaction in which the predecessor&#8217;s existence ceased upon consummation of the transaction.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#8221;Expenses&#8221;&nbsp;includes attorney&#8217;s fees.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(4)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;Official capacity&#8221;&nbsp;means the following:</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:18.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">When used with respect to a director, the office of director in the corporation; and</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:18.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">When used with respect to a person other than a director as contemplated in subsection (j), the elective or appointive office in the corporation held by the officer, or the employment or agency relationship undertaken by the employee or agent in behalf of the corporation.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(iii)</p>
			</td>
			<td style="vertical-align:top;width:18.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Official capacity&#8221;&nbsp;does not include service for any other foreign or domestic corporation or any partnership, joint venture, trust, other enterprise, or employee benefit plan.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(5)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;Party&#8221;&nbsp;includes a person who was, is, or is threatened to be made a named defendant or respondent in a proceeding.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(6)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;Proceeding&#8221;&nbsp;means any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(b) <i>Permitted indemnification of director</i>. &#8212;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A corporation may indemnify any director made a party to any proceeding by reason of service in that capacity unless it is established that:</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The act or omission of the director was material to the matter giving rise to the proceeding; and</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Was committed in bad faith; or</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Was the result of active and deliberate dishonesty; or</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The director actually received an improper personal benefit in money, property, or services; or</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(iii)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the case of any criminal proceeding, the director had reasonable cause to believe that the act or omission was unlawful.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:18.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indemnification may be against judgments, penalties, fines, settlements, and reasonable expenses actually incurred by the director in connection with the proceeding.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:18.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">However, if the proceeding was one by or in the right of the corporation, indemnification may not be made in respect of any proceeding in which the director shall have been adjudged to be liable to the corporation.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:44.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;(3) (i) The termination of any proceeding by judgment, order, or settlement does not create a presumption that the</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;director did not meet the requisite standard of conduct set forth in this subsection.</p>
			</td>
			<td style="vertical-align:top;width:0.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:18.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The termination of any proceeding by conviction, or a plea of nolo contendere or its equivalent, or an entry of an order of probation prior to judgment, creates a rebuttable presumption that the director did not meet that standard of conduct.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(4)</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:19.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A corporation may not indemnify a director or advance expenses under this section for a proceeding brought by that director against the corporation, except:</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For a proceeding brought to enforce indemnification under this section; or</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:1.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the charter or bylaws of the corporation, a resolution of the board of directors of the corporation, or an agreement approved by the board of directors of the corporation to which the corporation is a party expressly provide otherwise.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(c) <i>No indemnification of director liable for improper personal benefit</i>. &#8212; A director may not be indemnified under subsection (b) of this section in respect of any proceeding charging improper personal benefit to the director, whether or not involving action in the director&#8217;s official capacity, in which the director was adjudged to be liable on the basis that personal benefit was improperly received.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(d) <i>Required indemnification against expenses incurred in successful defense</i> &#8212; Unless limited by the charter:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A director who has been successful, on the merits or otherwise, in the defense of any proceeding referred to in subsection (b) of this section shall be indemnified against reasonable expenses incurred by the director in connection with the proceeding.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A court of appropriate jurisdiction, upon application of a director and such notice as the court shall require, may order indemnification in the following circumstances:</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If it determines a director is entitled to reimbursement under paragraph (1) of this subsection, the court shall order indemnification, in which case the director shall be entitled to recover the expenses of securing such reimbursement; or</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If it determines that the director is fairly and reasonably entitled to indemnification in view of all the relevant circumstances, whether or not the director has met the standards of conduct set forth in subsection (b) of this section or has been adjudged liable under the circumstances described in subsection (c) of this section, the court may order such indemnification as the court shall deem proper. However, indemnification with respect to any proceeding by or in the right of the corporation or in which liability shall have been adjudged in the circumstances described in subsection (c) shall be limited to expenses.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A court of appropriate jurisdiction may be the same court in which the proceeding involving the director&#8217;s liability took place.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(e) <i>Determination that indemnification is proper</i>. &#8212;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:middle;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indemnification under subsection (b) of this section may not be made by the corporation unless authorized for a specific proceeding after a determination has been made that indemnification of the director is permissible in the circumstances because the director has met the standard of conduct set forth in subsection (b) of this section.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:middle;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Such determination shall be made:</p>
			</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By the board of directors by a majority vote of a quorum consisting of directors not, at the time, parties to the proceeding, or, if such a quorum cannot be obtained, then by a majority vote of a committee of the board consisting solely of two or more directors not, at the time, parties to such proceeding and who were duly designated to act in the matter by a majority vote of the full board in which the designated directors who are parties may participate;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;By special legal counsel selected by the board of directors or a committee of the board by vote as set forth in subparagraph (i) of this paragraph, or, if the requisite quorum of the full board cannot be obtained therefor and the committee cannot be established, by a majority vote of the full board in which directors who are parties may participate; or</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(iii)</p>
			</td>
			<td style="vertical-align:top;width:18.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By the stockholders.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;(3)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Authorization of indemnification and determination as to reasonableness of expenses shall be made in the same manner as the determination that indemnification is permissible. However, if the determination that indemnification is permissible is made by special legal counsel, authorization of indemnification and determination as to reasonableness of expenses shall be made in the manner specified in subparagraph (ii) of paragraph (2) of this subsection for selection of such counsel.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(4)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Shares held by directors who are parties to the proceeding may not be voted on the subject matter under this subsection.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(f) <i>Payment of expenses in advance of final disposition of action</i>. &#8212;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:middle;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reasonable expenses incurred by a director who is a party to a proceeding may be paid or reimbursed by the corporation in advance of the final disposition of the proceeding upon receipt by the corporation of:</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:91.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A written affirmation by the director of the director&#8217;s good faith belief that the standard of conduct necessary for indemnification by the corporation as authorized in this section has been met; and</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:91.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A written undertaking by or on behalf of the director to repay the amount if it shall ultimately be determined that the standard of conduct has not been met.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;(2)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The undertaking required by subparagraph (ii) of paragraph (1) of this subsection shall be an unlimited general obligation of the director but need not be secured and may be accepted without reference to financial ability to make the repayment.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Payments under this subsection shall be made as provided by the charter, bylaws, or contract or as specified in subsection (e) of this section.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(g) <i>Validity of indemnification provision</i>. &#8212; The indemnification and advancement of expenses provided or authorized by this section may not be deemed exclusive of any other rights, by indemnification or otherwise, to which a director may be entitled under the charter, the bylaws, a resolution of stockholders or directors, an agreement or otherwise, both as to action in an official capacity and as to action in another capacity while holding such office.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(h) <i>Reimbursement of director</i>&#8217;<i>s expenses incurred while appearing as witness</i>. &#8212; This section does not limit the corporation&#8217;s power to pay or reimburse expenses incurred by a director in connection with an appearance as a witness in a proceeding at a time when the director has not been made a named defendant or respondent in the proceeding.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(i) <i>Director</i>&#8217;<i>s service to employee benefit plan</i>. &#8212; For purposes of this section:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The corporation shall be deemed to have requested a director to serve an employee benefit plan where the performance of the director&#8217;s duties to the corporation also imposes duties on, or otherwise involves services by, the director to the plan or participants or beneficiaries of the plan;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Excise taxes assessed on a director with respect to an employee benefit plan pursuant to applicable law shall be deemed fines; and</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Action taken or omitted by the director with respect to an employee benefit plan in the performance of the director&#8217;s duties for a purpose reasonably believed by the director to be in the interest of the participants and beneficiaries of the plan shall be deemed to be for a purpose which is not opposed to the best interests of the corporation.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(j) <i>Officer, employee or agent</i>. &#8212; Unless limited by the charter:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">An officer of the corporation shall be indemnified as and to the extent provided in subsection (d) of this section for a director and shall be entitled, to the same extent as a director, to seek indemnification pursuant to the provisions of subsection (d);</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A corporation may indemnify and advance expenses to an officer, employee, or agent of the corporation to the same extent that it may indemnify directors under this section; and</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A corporation, in addition, may indemnify and advance expenses to an officer, employee, or agent who is not a director to such further extent, consistent with law, as may be provided by its charter, bylaws, general or specific action of its board of directors, or contract.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(k) <i>Insurance or similar protection</i>. &#8212;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:middle;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee, or agent of the corporation, or who, while a director, officer, employee, or agent of the corporation, is or was serving at the request of the corporation as a director, officer, partner, trustee, employee, or agent of another foreign or domestic corporation, partnership, joint venture, trust, other enterprise, or employee benefit plan against any liability asserted against and incurred by such person in any such capacity or arising out of such person&#8217;s position, whether or not the corporation would have the power to indemnify against liability under the provisions of this section.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A corporation may provide similar protection, including a trust fund, letter of credit, or surety bond, not inconsistent with this section.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:19%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The insurance or similar protection may be provided by a subsidiary or an affiliate of the corporation.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(l) <i>Report of indemnification to stockholders</i>. &#8212; Any indemnification of, or advance of expenses to, a director in accordance with this section, if arising out of a proceeding by or in the right of the corporation, shall be reported in writing to the stockholders with the notice of the next stockholders&#8217; meeting or prior to the meeting.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Paragraph B. of Article Tenth of our amended and restated certificate of incorporation provides:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;The Corporation, to the full extent permitted by Section 2-418 of the MGCL, as amended from time to time, shall indemnify all persons whom it may indemnify pursuant thereto. Expenses (including attorneys&#8217; fees) incurred by an officer or director in defending any civil, criminal, administrative, or investigative action, suit or proceeding or which such officer or director may be entitled to indemnification hereunder shall be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the Corporation as authorized hereby.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Article XI of our Bylaws provides for indemnification of any of our directors, officers, employees or agents for certain matters in accordance with Section 2-418 of the Maryland General Corporation Law.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 7. Exemption from Registration Claimed.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Not applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 8. Exhibits.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following is a list of exhibits filed as a part of this Registration Statement which are incorporated herein:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></p>
			</td>
			<td style="vertical-align:top;width:0.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:18.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.1</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_576373.htm" style="-sec-extract:exhibit;">Opinion&nbsp;of Olshan Frome Wolosky LLP*</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:18.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518517002130/indiaglobal-def14a100517.htm" style="-sec-extract:exhibit;">2018&nbsp;Omnibus Incentive Plan of IGC Pharma, Inc. (1)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.2</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_575425.htm" style="-sec-extract:exhibit;">Form of Restricted&nbsp;Stock Unit Agreement *</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.3</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518521001863/ex_318373.htm" style="-sec-extract:exhibit;">Form&nbsp;of Stock Option Agreement (2)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.1%;">10.4</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:18.9%;"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523000688/ex_541546.htm" style="-sec-extract:exhibit;">Form&nbsp;of Share Purchase Agreement (3)</a></td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:18.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_575426.htm" style="-sec-extract:exhibit;">Consent&nbsp;of Independent Registered Public Accounting Firm*</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.2</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:18.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_576373.htm" style="-sec-extract:exhibit;">Consent&nbsp;of Olshan Frome Wolosky LLP (contained in Exhibit 5.1)*</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">24.1</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:18.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#sig" style="-sec-extract:exhibit;">Power of Attorney (included on the signature page of this registration statement)*</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">107</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:18.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_575427.htm" style="-sec-extract:exhibit;">Filing Fee Table</a></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Filed herewith.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1) Previously filed with the Securities Exchange Commission on October 10, 2017 as Exhibit 10-1 to the Definitive Proxy Statement on Form DEF 14A and incorporated herein by reference.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2) Previously filed with the Securities Exchange Commission on December 23, 2021 as Exhibit 10.2 to the Registration Statement on Form S-8 and incorporated herein by reference.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3) Previously filed with the Securities Exchange Commission on July 7, 2023 as Exhibit 10.1 to the Current Report on Form 8-K and incorporated herein by reference.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9. Undertakings.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a) The undersigned registrant hereby undertakes:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Filing Fee Tables&#8221; or &#8220;Calculation of Registration Fee&#8221; table, as applicable, in the effective registration statement;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:1pt;">Provided, however, that paragraphs (a)(1)(i) and (a)(l)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement; and</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:1pt;">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:1pt;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="sig" name="sig" title="sig"></a>SIGNATURES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:10.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>IGC PHARMA, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:9.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: October 3, 2023</p>
			</td>
			<td style="vertical-align:middle;width:0.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Claudia Grimaldi</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:11.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:9.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Claudia Grimaldi</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:11.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:9.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vice President (Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:21.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:22.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: October 3, 2023</p>
			</td>
			<td style="vertical-align:middle;width:1.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:21.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Ram Mukunda</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:24.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:21.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ram Mukunda</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:24.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:21.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Chief Executive Officer and President</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><a id="poa" name="poa" title="poa"></a>KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ram Mukunda as true and lawful attorney-in-fact and agent with full power of substitution and resubstitution and for him/her and in his/her name, place and stead, in any and all capacities to sign any and all amendments (including pre-effective and post-effective amendments) to this Registration Statement, as well as any new registration statement filed to register additional securities pursuant to Rule 462(b) under the Securities Act, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates stated.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:19.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>IGC PHARMA, INC.</b>&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: October 3, 2023</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/Ram Mukunda</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ram Mukunda</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Chief Executive Officer and President (Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:19.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: October 3, 2023</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Claudia Grimaldi</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Claudia Grimaldi</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Vice President (Principal Financial Officer)</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: October 3, 2023</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Rohit Goel</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rohit Goel</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General Manager (Principal Accounting Officer)</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: October 3, 2023</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Richard Prins</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Richard Prins</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: October 3, 2023</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ James Moran</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">James Moran</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:16.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex_576373.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html><head>
	<title>ex_576373.htm</title>
	<!-- Generated by ThunderDome Portal - 10/3/2023 11:22:39 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT 5.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">OLSHAN FROME WOLOSKY LLP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1325 Avenue of the Americas, 15th Floor</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">New York, New York 10019</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">IGC Pharma, Inc.<br>
10224 Falls Road,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Potomac, Maryland 20854</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:29pt;"><u>Re: Registration Statement on Form S-8</u><br>
<br>
<u>Ladies and Gentlemen:</u><br>
<br>
We have acted as counsel to IGC Pharma, Inc., a Maryland corporation (the &#8220;Company&#8221;), in connection with the filing of its registration statement on Form S-8 (the &#8220;Registration Statement&#8221;) relating to the registration of&nbsp; 4,000,000 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share&nbsp; issuable pursuant to the terms and in the manner set forth in the Company&#8217;s 2018 Omnibus Plan (the &#8220;Plan&#8221;) and up to 6,000,000 shares that may be issued pursuant to other grants (the &#8220;Special Grants&#8221;).<br>
<br>
This opinion letter is being delivered at the request of the Company and in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated by the Securities and Exchange Commission.<br>
<br>
We advise you that we have examined originals or copies certified or otherwise identified to our satisfaction of the Registration Statement, the Plan, the Articles of Incorporation and By-laws, each as amended, and corporate proceedings of the Company, and such other documents, instruments and certificates of officers and representatives of the Company and of public officials, and we have made such examination of law, as we have deemed appropriate as the basis for the opinion hereinafter expressed. In making such examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity and completeness of documents submitted to us as originals, the conformity to original documents of documents submitted to us as certified or photostatic copies, and the authenticity and completeness of the originals of such latter documents.<br>
<br>
Based upon the foregoing, we are of the opinion that the Shares to be issued under the Plan and Special Grants, when issued pursuant to the terms and in the manner set forth in the Plan and Special Grants, will be duly and validly issued, fully paid and non-assessable.<br>
<br>
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby concede that our firm is within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended or the rules and regulations of the Commission.<br>
<br>
Very truly yours,<br>
<br>
/s/ OLSHAN FROME WOLOSKY LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">OLSHAN FROME WOLOSKY LLP<b> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex_575425.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html><head>
	<title>ex_575425.htm</title>
	<!-- Generated by ThunderDome Portal - 9/30/2023 4:32:45 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>IGC PHARMA, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2018 OMNIBUS INCENTIVE PLAN</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Notice of restricted stock unit award</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:18.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Participant Name and Address:</b></p>
			</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">You (the &#8220;Participant&#8221;) have been granted restricted stock units (&#8220;Restricted Stock Units&#8221; or &#8220;RSUs&#8221;), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the &#8220;Notice&#8221;), the IGC Pharma, Inc. 2018 Omnibus Incentive Plan the &#8220;Plan&#8221;) and the Restricted Stock Unit Award Agreement (the &#8220;RSU Agreement&#8221;) attached hereto, as follows. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:15.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Date of Grant:</b></p>
			</td>
			<td style="vertical-align:top;width:29.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Number of RSUs</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Type of Grant:</b></p>
			</td>
			<td style="vertical-align:top;width:29.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-Qualified Restricted Stock Units</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Vesting:</b></p>
			</td>
			<td style="vertical-align:top;width:29.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vesting schedule is set out in Table 1 of this Notice.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="3" style="vertical-align: top; width: 43.8%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table 1: Vesting of RSUs</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 16%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Event</b></p>
			</td>
			<td style="vertical-align: top; width: 5.9%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares</b></p>
			</td>
			<td style="vertical-align: top; width: 21.9%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Comments</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 16%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Advancement of IGC AD1</b></p>
			</td>
			<td style="vertical-align: top; width: 5.9%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.9%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Must be employed with IGC</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 16%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.9%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.9%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 16%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.9%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.9%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 16%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.9%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.9%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 16%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.9%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.9%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 16%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.9%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.9%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid black; vertical-align: top; width: 16%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Subtotal</b>&nbsp;&nbsp;</p>
			</td>
			<td style="border-bottom: 1px solid black; vertical-align: top; width: 5.9%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="border: 1px solid black; vertical-align: top; width: 21.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The total vests at Phase 3 removal of clinical hold</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="3" style="vertical-align: top; width: 43.2%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table 1: Vesting of RSUs (continued)</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 15.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Event</b></p>
			</td>
			<td style="vertical-align: top; width: 5.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares</b></p>
			</td>
			<td style="vertical-align: top; width: 21.6%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Comments</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 15.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Advancement of Stock Price</b></p>
			</td>
			<td style="vertical-align: top; width: 5.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.6%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 15.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.6%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 15.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.6%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 15.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.6%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 15.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Subtotal</b>&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 5.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.6%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 15.8%; border-top: 1px solid black; border-bottom: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Total RSUs Award</b>&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 5.8%; border-top: 1px solid black; border-bottom: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.6%; border: 1px solid black;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the Company and the Participant have executed this Notice and agree that the Restricted Stock Units are to be governed by the terms and conditions of this Notice, the Plan, and the RSU Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:22.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IGC PHARMA, INC.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS NOTICE, THE RSU AGREEMENT, OR THE PLAN SHALL CONFER UPON THE PARTICIPANT ANY RIGHT WITH RESPECT TO FUTURE AWARDS OR CONTINUATION OF THE PARTICIPANT&#8217;S EMPLOYMENT WITH OR SERVICE TO THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE PARTICIPANT&#8217;S RIGHT OR THE RIGHT OF THE COMPANY TO TERMINATE THE PARTICIPANT&#8217;S EMPLOYMENT WITH OR SERVICE TO THE COMPANY, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT NOTICE. THE PARTICIPANT ACKNOWLEDGES THAT UNLESS THE PARTICIPANT HAS A WRITTEN EMPLOYMENT AGREEMENT WITH THE COMPANY TO THE CONTRARY, THE PARTICIPANT&#8217;S STATUS IS AT WILL.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Participant acknowledges receipt of a copy of the Plan and the RSU Agreement and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts the Restricted Stock Units subject to all of the terms and provisions hereof and thereof. The Participant has reviewed this Notice, the Plan, and the RSU Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Notice, and fully understands all provisions of this Notice, the Plan and the RSU Agreement. The Participant hereby agrees that all questions of interpretation and administration relating to this Notice, the Plan and the RSU Agreement shall be resolved by the Committee in accordance with Section 12 of the RSU Agreement. The Participant further agrees to the venue selection in accordance with Section 13 of the RSU Agreement. The Participant further agrees to notify the Company upon any change in the residence address indicated in this Notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Signed: <u>/s/&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Participant</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>IGC PHARMA, INC. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2018 OMNIBUS INCENTIVE PLAN</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>RESTRICTED STOCK UNIT AGREEMENT</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Grant of Restricted Stock Units</u>. IGC Pharma, Inc. (the &#8220;Company&#8221;), hereby grants to the Participant (the &#8220;Participant&#8221;) named in the Notice of Restricted Stock Unit Award (the &#8220;Notice&#8221;), the number of restricted stock units (&#8220;Restricted Stock Units&#8221; or &#8220;RSUs&#8221;) indicated in the Notice, subject to the terms and provisions of the Notice, this Restricted Stock Unit Award Agreement (this &#8220;RSU Agreement&#8221;) set forth in the Notice, subject to the terms and provisions of the Notice, this RSU Agreement, and Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;Plan&#8221;), which are incorporated herein by reference. Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Company</u>&#8217;<u>s Obligation to Pay</u>. Each Restricted Stock Unit represents the right to receive upon vesting thereof, as applicable, (x) one share of Common Stock or (y) cash equal to the Fair Market Value of the Restricted Stock Unit, in each case subject to Participant satisfying any applicable tax withholding obligations. Unless and until the Restricted Stock Units will have vested in the manner set forth in the Notice and the Plan, Participant will have no right to payment of any such Restricted Stock Units.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Vesting Schedule</u>. Except as specifically provided in Sections 4 and 5 below, the Restricted Stock Units awarded by the Notice and this RSU Agreement will vest in accordance with the &#8220;Vesting Schedule&#8221; set forth in Table 1 in the Notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><u>Termination of Service</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;"><u>Termination for Cause or Resignation of Employment</u>. If Participant&#8217;s employment is terminated by the Company for Cause, or Participant resigns his or her employment with the Company, then any unvested RSUs will be forfeited. The Participant&#8217;s employment or other service shall be considered to have been terminated for Cause if the Company determines, within 30 days after the Participant s resignation, that termination for Cause was warranted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;"><u>Termination without Cause</u>. If Participant&#8217;s employment is terminated by the Company other than for Cause (including for death or Disability), then Participant shall be entitled to partial vesting for the year in which the termination is effective depending upon the number of weeks that Participant has worked during the applicable year, all remaining RSUs shall be forfeited. Notwithstanding the foregoing, if the Participant, prior to the Expiration Date, violates the restrictive covenants (including, without limitation, the non- competition, non-solicitation, or confidentiality provisions) of any employment contract, any noncompetition, non-solicitation, confidentiality or assignment agreement to which the Participant is a party, or any other agreement between the Participant and the Company, any RSUs shall be forfeited.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Transferability of RSUs</u>. Unless determined otherwise by the Committee, the RSUs may not be sold, pledged, assigned, hypothecated, or otherwise transferred by Participant in any manner other than by will or by the laws of descent and distribution. In accepting this RSU Agreement, the Participant agrees to be bound by any clawback policy that the Company has in place or may adopt in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><u>Tax Consequences</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">The Participant may incur tax liability as a result of the Participant&#8217;s disposition of the Shares. THE PARTICIPANT SHOULD CONSULT A TAX ADVISER BEFORE DISPOSING OF THE SHARES.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">The Company makes no representation that the RSUs will comply with Sections 409A and 457A of the Code and makes no undertaking to prevent Section 409A or 457A of the Code from applying to the RSUs or to mitigate its effects on any deferrals or payments made in respect of the RSUs. The Participant is encouraged to consult a tax adviser regarding the potential impact of Section 409A and 457A of the Code.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Stop-Transfer Notices</u>. In order to ensure compliance with the restrictions on transfer set forth in this RSU Agreement, the Notice or the Plan, the Company may issue appropriate &#8220;stop-transfer&#8221; instructions to its transfer agent, if any, and, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Refusal to Transfer</u>. The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this RSU Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Entire Agreement; Severability</u>. The Notice, the Plan and this RSU Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant&#8217;s interest except by means of a writing signed by the Company and the Participant. In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this RSU Agreement, the terms and conditions of the Plan shall prevail. Nothing in the Notice, the Plan and this RSU Agreement (except as expressly provided therein) is intended to confer any rights or remedies on any persons other than the parties. Should any provision of the Notice, the Plan or this RSU Agreement be determined to be illegal or unenforceable, such provision shall be enforced to the fullest extent allowed by law and the other provisions shall nevertheless remain effective and shall remain enforceable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Construction</u>. The captions used in the Notice and this RSU Agreement are inserted for convenience and shall not be deemed a part of the RSUs for construction or interpretation. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term &#8220;or&#8221; is not intended to be exclusive unless the context clearly requires otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Administration and Interpretation</u>. Any question or dispute regarding the administration or interpretation of the Notice, the Plan or this RSU Agreement shall be submitted by the Participant or by the Company to the Committee. The resolution of such question or dispute by the Committee shall be final and binding on all persons.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Governing Law; Venue</u>. The Notice, the Plan and this RSU Agreement are to be construed in accordance with and governed by the laws of the<b> </b>State of Maryland without regard to choice of law principles. The Company and the Participant agree that any suit, action, or proceeding arising out of or relating to the Notice, the Plan or this RSU Agreement shall be brought in the courts located in Maryland and that the parties shall submit to the jurisdiction of such court. The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court. If any one or more provisions of this Section 13 shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Notices</u>. All notices, requests, consents and other communications under this RSU Agreement shall be in writing and shall be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) If to the registered Holder of the RSU, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to the following address or to such other address as the Company may designate by notice to the Holders:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:1pt;">Address of Holder:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:1pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:1pt;">Address of Company:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:1pt;">IGC Pharma, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:1pt;">PO Box 60642</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:1pt;">Potomac MD 20859</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Counterparts</u>. The Notice may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Conflicts</u>. In the event of a conflict or inconsistency between the terms and conditions of this RSU Agreement and a written employment agreement between the Company and the Participant, the terms and conditions of such employment agreement shall control.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Clawback Policy</u>. Notwithstanding any other provision of this RSU Agreement or the Plan to the contrary, all RSUs, Shares or Common stock issued and/or amount paid pursuant to an equity award, and/or any amount received with respect to any sale of any such Shares, shall be subject to potential cancellation, recoupment, rescission, payback or other action in the event if: (a) the payment, grant or vesting of the RSUs was based on the achievement of financial results that were subsequently the subject of a restatement of the Company&#8217;s financial statements filed with the Securities and Exchange Commission and the amount of the compensation that would have been received by the Participant had the financial results been properly reported would have been lower than the amount actually received or (b) the Committee determines, in its sole discretion, exercised in good faith, that the Participant engaged in fraud or misconduct that caused or contributed to the need for the restatement. The Committee shall have full and final authority to make all determinations under this Section 17, including without limitation (i) whether this Section 17 applies and if so, the amount of the RSUs or Shares to be repaid or forfeited by the Participant and (ii) that it is in the best interests of the Company and its shareholders for the Participant to repay or forfeit all or any portion of the RSUs, Shares issues, or amount paid pursuant to an equity award. Repayment can be made from the proceeds of the sale of Company stock and the forfeiture of other outstanding awards. The remedy specified in this policy shall not be exclusive and shall be in addition to every other right or remedy at law or in equity that may be available to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">******************************************&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex_575426.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_575426.htm</title>
	<!-- Generated by ThunderDome Portal - 10/3/2023 10:15:59 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="ex_575426img001.jpg" src="ex_575426img001.jpg" style="width:626;height:129;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To the Board of Directors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">IGC Pharma, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference in this Registration Statement of IGC Pharma, Inc. on Form S-8 of our report dated July 7, 2023, on the financial statements of IGC Pharma, Inc. included in the Annual report on form 10-K for the fiscal year ended March 31, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>/s/ Manohar Chowdhry &amp; Associates</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:90.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Manohar Chowdhry &amp; Associates</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chennai, India</p>
			</td>
			<td style="vertical-align:top;width:113.8%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:&nbsp;October 3, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>ex_575427.htm
<DESCRIPTION>EXHIBIT FILING FEES
<TEXT>
<html><head>
	<title>ex_575427.htm</title>
	<!-- Generated by ThunderDome Portal - 10/3/2023 10:15:31 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 107</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Calculation of Filing Fee Table</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><u><b>Form S-8</b></u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Form Type)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><u><b>IGC Pharma, Inc.</b></u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in its Charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Newly Registered Securities</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 100%; margin-left: auto; margin-right: auto; border: 1px solid black;">

		<tr style="font-size: 8pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Security </b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Type</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Title of Each Class of </b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Securities to be<br>
			Registered</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fee </b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Calculation </b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Rule</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount to be Registered(1)</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Proposed Maximum </b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Offering Price Per Share(2)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 12.6%; border-bottom: 1px solid black; font-size: 8pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Maximum Aggregate </b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Offering Price(3)</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fee </b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Rate</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount of </b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Registration Fee(2)</b></p>
			</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Equity</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Common Stock, par value $0.01</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 12.6%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Rule 457(c) and (h)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">10,000,000</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">$0.36</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black; text-align: center;">$3,600,000</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">0.0001476</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt;">&nbsp;</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50.5%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total Offering Amounts</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">$3,600,000</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">$531.36</p>
			</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50.5%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total Fee Offsets</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.6%; font-size: 8pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">$0.00</p>
			</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td colspan="4" style="vertical-align: bottom; width: 50.5%; font-size: 8pt; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net Fee Due</b></p>
			</td>
			<td style="vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="vertical-align: top; width: 12.6%; font-size: 8pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="vertical-align: top; width: 12.6%; font-size: 8pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">$531.36</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="3" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Registration Statement registers (i) the issuance of 4,000,000 shares of common stock $0.0001 par value (the &#8220;Common Stock&#8221;) of IGC Pharma, Inc. (the &#8220;Registrant&#8221;) issuable pursuant to the 2018 Omnibus Incentive Plan of the Registrant (the &#8220;2018 Plan&#8221;) and (ii) 6,000,000 shares of Common Stock of the Registrant approved by the Registrant&#8217;s stockholders on September 9, 2022 and August 18, 2023, to be issued, from time to time and at the Company&#8217;s Board of Directors&#8217;&nbsp;discretion, to current and new directors, officers, employees, and advisor. The number of shares available for issuance under the 2018 Plan, provides that the total number of shares subject to the 2018 Plan may be increased as of April 1 of each year by a number of shares equal to 15% of the outstanding shares of the Company on such date less 28,272,667.</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457 promulgated under the Securities Act.</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(3)</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Registrant&#8217;s common stock ($0.36) as reported on the NYSE American on September 27, 2023, which is within five business days of October 3, 2023.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex_575426img001.jpg
<TEXT>
begin 644 ex_575426img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "! G(# 2(  A$! Q$!_\0
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M[6/<]:HKE/!7C,>,(+N3[#]D^SN$V^=OW9&<_=&*ZOM4EIIJZ%HHHH&%%%%
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M444 %%%% !1110 4444 >5_&1O,_L"V^\'N68KCKP!_6L_PWJI\+VGC?1W8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3'7D\
M_I10 M%)CIR?\:6@ HHHH **** "BDQSG)Z=*3!X^8_IS0 ZBFX/]X]<_P#U
MJ,'GYC^G% #J*;S_ 'CTQV_.CGU/3VH =13<'U/7VHP?[QZY_P#K4 .HIN#S
M\Q_3BCG^\>F.WYT .HIO/')_3FE'US0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>igcpharma20230929_s8img001.jpg
<TEXT>
begin 644 igcpharma20230929_s8img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% '4# 2(  A$! Q$!_\0
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M-?B!#X=9K"Q1+C4B,MN^Y"#TW>I]OSJ;X=>(KWQ#H5Q)J$@EN8+@H9-@7*D
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AU:\TZZGB74YA/);X4QQO@Y*#'&<\_04444I3E)W8'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>igcpharma20230929_s8img002.jpg
<TEXT>
begin 644 igcpharma20230929_s8img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% '4# 2(  A$! Q$!_\0
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M-?B!#X=9K"Q1+C4B,MN^Y"#TW>I]OSJ;X=>(KWQ#H5Q)J$@EN8+@H9-@7*D
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AU:\TZZGB74YA/);X4QQO@Y*#'&<\_04444I3E)W8'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
